南方科技大学知识苑(SUSTech KC): Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).

题名	Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
作者	Mai, Hai-Qiang ; Chen, Qiu-Yan ; Chen, Dong-Ping ; Hu, Chaosu ; Yang, Kunyu ; Wen, Jiyu ; Li, Jin-Gao ; Shi, Yingrui ; Jin, Feng ; Xu, Ruilian ; Pan, Jian-Ji ; Qu, Shenhong ; Li, Ping ; Hu, Chunhong ; Liu, Yi-Chun ; Jiang, Yi ; He, Xia ; Wang, Hung-Ming ; Lim, Darren Wan-Teck ; Xu, Rui-Hua
发表日期	2023-06-01
会议名称	Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
ISSN	0732-183X
EISSN	1527-7755
会议录名称	JOURNAL OF CLINICAL ONCOLOGY
卷号	41
期号	16
会议日期	JUN 02-06, 2023
会议地点	Chicago, IL
出版地	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
出版者	LIPPINCOTT WILLIAMS & WILKINS
学校署名	其他
语种	英语
相关链接	[来源记录]
收录类别	SCI ; CPCI-S
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:001053772003130
ESI学科分类	CLINICAL MEDICINE
来源库	Web of Science
引用统计	被引频次[WOS]：1
成果类型	会议论文
条目标识符	http://sustech.caswiz.com/handle/2SGJ60CL/571745
专题	南方科技大学第一附属医院
作者单位	1.Sun Yat Sen Univ, Ctr Canc, Dept Nasopharyngeal Carcinoma, Guangzhou, Peoples R China 2.Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China 3.Guangzhou Med Univ, Affiliated Canc Hosp, Guangzhou, Peoples R China 4.Fudan Univ, Ctr Canc, Shanghai, Peoples R China 5.Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China 6.Guangdong Med Univ, Affiliated Hosp, Zhanjiang, Peoples R China 7.Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China 8.Hunan Canc Hosp, Changsha, Peoples R China 9.Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China 10.Guizhou Med Univ, Doctoral Res Start Up Fund Project, Affiliated Hosp, Guiyang, Guizhou, Peoples R China 11.Jinan Univ, Secondary Clin Med Coll, Shenzhen Peoples Hosp, Jinan, Peoples R China 12.Southern Univ Sci & Technol, Affiliated Hosp 1, Shenzhen, Peoples R China 13.Fujian Canc Hosp, Fuzhou, Peoples R China 14.Peoples Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China 15.Sichuan Univ, West China Hosp, Chengdu, Peoples R China 16.Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China 17.Taichung Vet Gen Hosp, Dept Radiat Oncol, Taichung, Taiwan 18.Shantou Univ, Canc Hosp, Coll Med, Shantou, Peoples R China 19.Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China 20.Chang Gung Mem Hosp, Div Hematol Oncol, Dept Internal Med, Taoyuan, Taiwan 21.Natl Canc Ctr Singapore, Singapore, Singapore 22.Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China
推荐引用方式 GB/T 7714	Mai, Hai-Qiang,Chen, Qiu-Yan,Chen, Dong-Ping,et al. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).[C]. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA:LIPPINCOTT WILLIAMS & WILKINS,2023.